Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe asthma that has been billed as a major new product for the drugmaker. In the ...
The man's family later sued OptumRx and Walgreens, claiming they didn't offer alternatives after his regular inhaler's price increased dramatically.
NICE has recommended dupilumab, a first-of-its-kind targeted COPD treatment that reduces flare-ups and improves lung function ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results